CA3069586A1 - New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates - Google Patents

New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates Download PDF

Info

Publication number
CA3069586A1
CA3069586A1 CA3069586A CA3069586A CA3069586A1 CA 3069586 A1 CA3069586 A1 CA 3069586A1 CA 3069586 A CA3069586 A CA 3069586A CA 3069586 A CA3069586 A CA 3069586A CA 3069586 A1 CA3069586 A1 CA 3069586A1
Authority
CA
Canada
Prior art keywords
alkyl
thio
cyclic monophosphorothioate
aryl
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069586A
Other languages
English (en)
French (fr)
Inventor
Hans-Gottfried Genieser
Frank Schwede
Andreas Rentsch
Per Ekstrom
Francois Paquet-Durand
Valeria Marigo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mireca Medicines GmbH
Original Assignee
Mireca Medicines GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mireca Medicines GmbH filed Critical Mireca Medicines GmbH
Publication of CA3069586A1 publication Critical patent/CA3069586A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3069586A 2016-07-11 2017-06-29 New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates Pending CA3069586A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16178924 2016-07-11
EP16178924.3 2016-07-11
PCT/EP2017/066113 WO2018010965A1 (en) 2016-07-11 2017-06-29 New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates

Publications (1)

Publication Number Publication Date
CA3069586A1 true CA3069586A1 (en) 2018-01-18

Family

ID=56411445

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069586A Pending CA3069586A1 (en) 2016-07-11 2017-06-29 New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates

Country Status (5)

Country Link
US (2) US11407781B2 (enExample)
EP (1) EP3481842A1 (enExample)
JP (2) JP7113409B2 (enExample)
CA (1) CA3069586A1 (enExample)
WO (1) WO2018010965A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069586A1 (en) 2016-07-11 2018-01-18 Mireca Medicines Gmbh New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates
WO2018041942A1 (en) * 2016-08-31 2018-03-08 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh New polymer linked multimers of guanosine-3', 5'-cyclic monophosphates
JP7161760B2 (ja) * 2017-02-03 2022-10-27 国立大学法人東北大学 複素環化合物
EP3679935A4 (en) * 2017-07-10 2021-04-21 Tohoku University REMOVAL AGENT WITH AUTOPHAGIC MECHANISM OF DAMAGED MITOCHONDRIA
CN117999269A (zh) 2021-09-06 2024-05-07 米雷卡医药有限公司 用于生产环状鸟苷-单磷酸酯类似物的改进方法
CA3267932A1 (en) 2022-10-05 2024-04-11 Mireca Medicines Gmbh MICROPARCEL AND IMPLANT FORMULATIONS FOR ANALOGUE CGMP THERAPY
EP4598580A1 (en) 2022-10-06 2025-08-13 Mireca Medicines GmbH Conjugates for neuroretinal drug delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007108A1 (en) 1988-02-01 1989-08-10 Bernd Jastorff Process for producing nucleoside-3',5'-cyclophosphates and nucleoside-3',5'-cyclothiophosphates
US5625056A (en) 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
WO1999025384A2 (en) * 1997-11-17 1999-05-27 University Of Miami Multimeric tethered ligands and their use in receptor-ligand interactions
MX2008006550A (es) 2005-11-23 2008-09-23 Ironwood Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos gastrointestinales.
EP2125027A2 (en) 2007-03-12 2009-12-02 Nektar Therapeutics De novo synthesis of conjugates
WO2009026697A1 (en) 2007-08-28 2009-03-05 University Of Manitoba A method of reducing a vasodilatory response using a guanylate cyclase pathway inhibitor or an h2o2 reducing agent
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
WO2012130829A1 (en) 2011-03-29 2012-10-04 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh New boranophosphate analogues of cyclic nucleotides
SG11201705913UA (en) 2015-01-23 2017-08-30 Dynavax Tech Corp Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof
US10322087B2 (en) 2015-03-16 2019-06-18 Mireca Medicines Gmbh Targeted liposomal delivery of cGMP analogues
WO2018009587A1 (en) 2016-07-05 2018-01-11 Orbis Wheels, Inc. Multi-wheel transmission
CA3069586A1 (en) 2016-07-11 2018-01-18 Mireca Medicines Gmbh New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates

Also Published As

Publication number Publication date
EP3481842A1 (en) 2019-05-15
JP2022140440A (ja) 2022-09-26
JP7113409B2 (ja) 2022-08-05
JP7672368B2 (ja) 2025-05-07
US11407781B2 (en) 2022-08-09
US20220402964A1 (en) 2022-12-22
US12583882B2 (en) 2026-03-24
US20190292214A1 (en) 2019-09-26
WO2018010965A1 (en) 2018-01-18
JP2019529523A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
US12583882B2 (en) Equatorially modified polymer linked multimers of guansine-3′, 5′-cyclic monophosphates
CN102596204B (zh) 新的核酸前药及其使用方法
EP1511757B1 (en) New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
JP4624104B2 (ja) オリゴヌクレオチド結合体
JP7564087B2 (ja) アンチセンス送達のための三量体ペプチド
US9572898B2 (en) Functionalized fluorine containing phthalocyanine molecules
US12384813B2 (en) Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates
BRPI0906104B1 (pt) Derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto
Amato et al. Tailoring a lead-like compound targeting multiple G-quadruplex structures
WO2022100696A1 (zh) 多特异生物偶联连接臂及其合成方法
CN108136041A (zh) 寡核苷酸缀合方法
CN109224080A (zh) 一种支载核苷类抗肿瘤药物的靶向纳米载体及其制备方法和应用
CN110023322A (zh) 新的双环核苷和由其制备的寡聚体
JP2022533421A (ja) 核酸、薬物組成物及び複合体ならびに調製方法と使用
JP4854913B2 (ja) オリゴヌクレオチド結合体
Winkler et al. Oligonucleotide–polyamine conjugates: Influence of length and position of 2′-attached polyamines on duplex stability and antisense effect
EP4201429B1 (en) Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor
JP2024098512A (ja) アプタマー型マルチウォーヘッド共有結合性薬剤
WO2014093652A1 (en) Semi - synthetic mithramycin derivatives with anti-cancer activity
US20250171776A1 (en) Non-canonical cell-penetrating peptides for antisense oligomer delivery
JP2025541189A (ja) 腫瘍疾患および／または感染症の併用療法用キット
WO2024090491A1 (ja) コンジュゲート用細胞膜透過性ペプチド
WO2025261376A1 (zh) 肝外递送配体及其缀合物
WO2025140434A1 (zh) 一种肝靶向化合物及其在药物缀合物中的用途
CN120303002A (zh) 包含抗肿瘤剂的聚合化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220628

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250210

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250626

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250626